In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Intelligence

Set Alert for Market Intelligence

Big Pharma Licensing Growth Slows In 2016

Big pharma licensing deal volume grew 12% between 2012 and 2016, but according to a new report from Datamonitor Healthcare there were fewer deals and dollars attributed to partnerships in 2016.

BioPharmaceutical Deals Market Intelligence
Advertisement

Latest From Market Intelligence

Personalized Medicine: A Trip Down Memory Lane

Free article: What In Vivo has been saying about personalized medicine in this century.

BioPharmaceutical Personalized Medicine

One Size No Longer Fits All: The Personalized Medicine Trial Landscape

Success rates are higher for clinical trials that incorporate selective pharmacogenomics and pharmacogenetics (PGX) biomarkers, according to data from Informa's Trialtrove. Given the challenges of designing and administering trials to secure regulatory approval in areas of unmet medical need, the data provide some basis for optimism in realizing the promise of targeted, personalized therapies that improve health outcomes for individual patients.

Personalized Medicine Clinical Trials

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical

Deals In Depth: January 2017

Servier signed a $1.7 billion immuno-oncology deal with Pieris; Johnson & Johnson paid $30 billion to acquire Actelion and its key pulmonary arterial hypertension assets. Device fundraising was significantly boosted by Verily's $800 million investment from Temasek.

Deals BioPharmaceutical

Device/Diagnostics Quarterly Deal Statistics, Q4 2016

Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.

Deals Medical Device

In Vivo's Deals Of The Month, February 2017

Free article: In Vivo's editors pick February's most significant deals, including Seattle Genetics' new ADC and Integra's big bid in neurosurgery.

BioPharmaceutical Medical Device
See All
UsernamePublicRestriction

Register